Fig. 3: Comparison of effects of factors in participants who received two doses of ChAdOx1 or BNT162b2 or had natural SARS-CoV-2 infection. | Nature Medicine

Fig. 3: Comparison of effects of factors in participants who received two doses of ChAdOx1 or BNT162b2 or had natural SARS-CoV-2 infection.

From: Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Fig. 3

a, Effects on anti-spike IgG peak levels. b, Effects on anti-spike IgG half-lives. In total, 100,639 participants received two doses of ChAdOx1; 55,053 participants received two doses of BNT162b2; and 3,271 had natural infection. Mean estimates with 95% CrIs are presented. In b, 95% CrIs are truncated at −100 and 75 days for visualization.

Source data

Back to article page